NewslettersNeural Cell News The First-in-Class ERK Inhibitor Ulixertinib Shows Promising Activity in MAPK-Driven Pediatric Low-Grade Glioma Models By lbeveridge - July 27, 2022 0 Scientists investigated the anti-tumoral activity of ulixertinib monotherapy as well as in combination with MEK inhibitors, BH3-mimetics, or chemotherapy in pediatric low-grade gliomas. [Neuro-Oncology] Abstract